Australian researchers stopping melanoma in its tracks

Australian researchers stopping melanoma in its tracks

11 September 2017

A team of Australian researchers has made the ultimate move in the battle to beat melanoma, successfully trialling a combination of new treatments to stop the disease in its tracks and prevent it from spreading or metastasising to distant organs.

Melanoma is the deadliest form of skin cancer, with one Australian dying from advanced melanoma every five hours.

Ground-breaking results from two international clinical trials conducted by investigators at Melanoma Institute Australia are being presented today at one of the world’s largest medical oncology conferences, the European Society for Medical Oncology (ESMO) 2017 Congress in Spain. The research has also been published in the prestigious New England Journal of Medicine today.

The trials, COMBI-AD and CheckMate 238, proved successful in preventing the spread of disease in Stage III melanoma patients whose tumours had been surgically removed. Until now, these patients were at a high risk (40−70 per cent) of their disease progressing to advanced and fatal melanoma.

“These results will change the way we treat melanoma patients as well as their quality of life,” says study author Professor Georgina Long (pictured), Conjoint Medical Director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research at The University of Sydney. 

“Until now, Stage III melanoma patients who have had their tumours surgically removed have simply had to play the waiting game, to see if their melanoma would metastasise or spread. Living with such fear severely affected them and their loved ones.

“Results from these clinical trials suggest we can stop the disease in its tracks – effectively preventing it from spreading and saving lives. Our ultimate goal of making melanoma a chronic rather than a terminal illness is now so much closer to being achieved,” she said.

In the COMBI-AD trial, patients were randomised to receive a combination of targeted therapies (dabrafenib and trametinib) or placebo for 12 months. Targeted therapies block the action of a particular gene which is a driver for melanoma. It was aimed at patients who are BRAF positive. It not only prevented resected Stage III melanoma from recurring, but it increased overall survival.

The CheckMate 238 trial involved patients with high risk Stage III and Stage IV disease who had had all melanoma surgically removed. They were randomised to be treated with the immunotherapy nivolumab or ipilimumab for 12 months.  Immunotherapies reboot the immune system to attack the melanoma cells. Results showed nivolumab decreased the chance of relapse, and it had a superior safety profile over ipilimumab. This benefit was seen in patients regardless of BRAF mutation status. The follow up period is too short to yet determine long-term survival rates.

Research had already shown that targeted and immune therapies can successfully treat patients with advanced (Stage IV) melanoma that could not be removed surgically.

These clinical trials are the first in the world to give the treatments to melanoma patients at an earlier stage of the disease to prevent spread and recurrence.

“These clinical trials show we now have ammunition to prevent melanoma spreading and progressing, which until now was a critical area of disease behaviour where we had no control,” Professor Long said.

“This will change how melanoma is treated around the world, as we no longer have to passively wait to see if the melanoma spreads.

“We can now actively and effectively attack the melanoma at an earlier stage, reducing the dreadful anxiety for patients about progressing to a potentially terminal illness and ensuring they have much better outcomes,” she said.  

History teacher and mother Renae Aslanis was a patient on the COMBI-AD trial. After having 10 lymph nodes removed, she decided to enter the clinical trial rather than just "watching and waiting". Now four-and-a-half years later, she is still "going strong"! Read more.

Download the media release

Renae

Publications:

MIA joins Sydney Health Partners
14 Dec 2021

MIA joins Sydney Health Partners

Sydney Health Partners' goal is to ensure world class research is successfully implemented & scaled-up to benefit patients & wider society.

Tags: melanoma
Olympians join forces for melanoma warning
13 Dec 2021

Olympians join forces for melanoma warning

Jana Pittman and Melinda Gainsford-Taylor urge Australians to be sun-safe and check their skin as they join the Game On Mole campaign in support of their much-loved coach

Tags: melanoma
MIA research wins Cancer Institute of NSW 'Wildfire Highly Cited Publication'
07 Dec 2021

MIA research wins Cancer Institute of NSW 'Wildfire Highly Cited Publication'

Cited an incredible 427 times around the world, showing its vital role in improving outcomes for people with advanced melanoma.

Tags: melanoma
Prof Richard Scolyer receives University of Tasmania Distinguished Alumni Award
06 Dec 2021

Prof Richard Scolyer receives University of Tasmania Distinguished Alumni Award

Honouring the exceptional impact of his work on communities around the world.

Tags: melanoma
MIA's Co-Medical Directors receive University of Sydney's Vice-Chancellor's Award for Outstanding Research
03 Dec 2021

MIA's Co-Medical Directors receive University of Sydney's Vice-Chancellor's Award for Outstanding Research

Awarded for their life-saving discoveries transforming melanoma patient care.

Tags: melanoma
Aussies urged to mark start of summer by checking their skin
01 Dec 2021

Aussies urged to mark start of summer by checking their skin

National day of action called amidst fears COVID lockdowns have deterred patients from seeking potentially life-saving medical treatment

Tags: melanoma
Prof Georgina Long AO awarded the 2021 Ramaciotti Medal for Excellence in Biomedical Research
24 Nov 2021

Prof Georgina Long AO awarded the 2021 Ramaciotti Medal for Excellence in Biomedical Research

Recognising her pioneering work in immunotherapy in melanoma, transforming the care of patients worldwide.

Tags: melanoma
AMC2021 conference wrap-up
23 Nov 2021

AMC2021 conference wrap-up

Clinicians and researchers from across Australia and beyond united online, bringing the AMC2021 conference theme of Promising Futures to life.

Tags: melanoma
Journalist and news reader Peter Overton our new National Ambassador
23 Nov 2021

Journalist and news reader Peter Overton our new National Ambassador

Melanoma Institute Australia is proud to announce that the Nine Network’s Peter Overton AM has joined us as a National Ambassador.

Tags: melanoma
MIA researchers feature on prestigious Highly Cited Researchers 2021 List
19 Nov 2021

MIA researchers feature on prestigious Highly Cited Researchers 2021 List

MIA is proud to announce that five of our researchers have been named on the Clarivate Annual Highly Cited Researchers™ 2021 list.

Tags: melanoma
New research into importance of skin surveillance to save lives from melanoma
04 Nov 2021

New research into importance of skin surveillance to save lives from melanoma

New research shows routine skin checks by a health professional, coupled with checking your own skin, are vital in saving lives from melanoma.

Tags: melanoma
Game On Mole - saving lives this summer
31 Oct 2021

Game On Mole - saving lives this summer

With new patient figures indicating people may have deferred skin checks during the pandemic our Game On Mole campaign is more important than ever. 

Tags: melanoma
Melanoma March physical events in 2022
22 Oct 2021

Melanoma March physical events in 2022

We are excited to announce a return to our much-loved physical Melanoma March events in March 2022! 

Tags: melanoma
Community Fundraising Wrap Up July-Sept 2021
15 Oct 2021

Community Fundraising Wrap Up July-Sept 2021

Read more about the wonderful MIA community fundraising initiatives held recently.

Tags: melanoma
Australian researchers spearhead paradigm shift in melanoma treatment
20 Sep 2021

Australian researchers spearhead paradigm shift in melanoma treatment

Drug therapy set to become standard treatment in high-risk early stage patients to stop disease spread

Tags: melanoma
Melanoma Bike Bash 2021: What a ride!
20 Sep 2021

Melanoma Bike Bash 2021: What a ride!

Over two fun, yet challenging, days in September an intrepid group of riders and crew successfully completed the annual Melanoma Bike Bash in WA!

Tags: melanoma
Prof Georgina Long AO awarded inaugural Outstanding Female Researcher Medal from AAHMS
16 Sep 2021

Prof Georgina Long AO awarded inaugural Outstanding Female Researcher Medal from AAHMS

Prof Long AO has been recognised by Australian Academy of Health and Medical Sciences for her transformative work advancing melanoma treatments.

Tags: melanoma
MIA researchers awarded $7.2m in NHMRC grants for health research
15 Sep 2021

MIA researchers awarded $7.2m in NHMRC grants for health research

Three MIA researchers at University of Sydney received grants to further their important melanoma research.

Tags: melanoma
Amie St Clair Ball in Wagga postponed for a third time
06 Sep 2021

Amie St Clair Ball in Wagga postponed for a third time

COVID restrictions continue to impact fundraising for melanoma services in Riverina.

Honouring Ben's life by supporting the next generation of melanoma researchers
30 Aug 2021

Honouring Ben's life by supporting the next generation of melanoma researchers

Ben Garrow lost his life to melanoma. In his honour his family has established a scholarship to support a PhD student whose work focuses on saving lives from melanoma.